CN Patent

CN120456907A — 急性白血病的治疗方法

Assigned to Kura Oncology Inc · Expires 2025-08-08 · 1y expired

What this patent protects

本文提供了治疗个体(诸如具有核仁磷蛋白1(NPM1)基因中的突变或赖氨酸[K]‑甲基转移酶2A(KMT2A)基因中的重排的个体)的急性白血病(诸如急性髓系白血病(AML))的方法，其中该方法包含以每日600毫克的剂量向该个体施用menin抑制剂齐托美尼。

USPTO Abstract

本文提供了治疗个体(诸如具有核仁磷蛋白1(NPM1)基因中的突变或赖氨酸[K]‑甲基转移酶2A(KMT2A)基因中的重排的个体)的急性白血病(诸如急性髓系白血病(AML))的方法，其中该方法包含以每日600毫克的剂量向该个体施用menin抑制剂齐托美尼。

Drugs covered by this patent

Patent Metadata

Patent number
CN120456907A
Jurisdiction
CN
Classification
—
Expires
2025-08-08
Drug substance claim
No
Drug product claim
No
Assignee
Kura Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.